[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100447533":3},{"organization":4,"armGroups":7,"interventions":59,"overallOfficials":72,"centralContacts":76,"locations":83,"responsibleParty":311,"collaborators":71,"id":313,"slug":314,"hasResults":315,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":71,"eligibilityCriteria":319,"healthyVolunteers":315,"sex":320,"minAge":321,"maxAge":71,"enrollmentInfo":322,"targetDuration":71,"studyType":325,"phases":326,"briefSummary":328,"conditions":329,"keywords":344,"overallStatus":100,"whyStopped":71,"lastUpdateSubmitDate":348,"lastUpdatePostDateStruct":349,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":357},{"fullName":5,"class":6},"Nurix Therapeutics, Inc.","INDUSTRY",[8,14,18,22,26,30,34,38,42,46,51,55],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1a Dose Escalation of NX-1607 (monotherapy)","EXPERIMENTAL","Multiple dose levels and dosing regimen of NX-1607 to be evaluated; determination of MTD\u002FPhase 1b recommended dose.",[13],"Drug: NX-1607",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 1a Food Effect","Impact of food on NX-1607 bioavailability and tolerability to be evaluated",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Phase 1b Dose Expansion in platinum-resistant EOC","Patients with platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Phase 1b Dose Expansion in advanced gastric\u002FGEJ cancer","Patients with recurrent, locally advanced, or metastatic gastric or GEJ adenocarcinoma",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Phase 1b Dose Expansion in HNSCC","Patients with recurrent, locally advanced, or metastatic HNSCC",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Phase 1b Dose Expansion in recurrent melanoma","Patients with recurrent and either metastatic or unresectable Melanoma",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Phase 1b Dose Expansion in advanced NSCLC","Patients with Stage IV NSCLC",[13],{"label":39,"type":10,"description":40,"interventionNames":41},"Phase 1b Dose Expansion in mCRPC","Patients with mCRPC who received a minimum of 2 prior lines of therapy in the advanced setting including androgen receptor-directed therapy and a taxane-based chemotherapy and has PSA or radiographic progression",[13],{"label":43,"type":10,"description":44,"interventionNames":45},"Phase 1b Dose Expansion in mixed solid tumor cohort","Cohort of mixed solid tumor indications consisting of patients with MPM, TNBC, locally advanced or metastatic urothelial cancer, cervical cancer, or DLBCL\u002FDLBCL-RT",[13],{"label":47,"type":10,"description":48,"interventionNames":49},"Phase 1a Dose Escalation of NX-1607 in combination with Paclitaxel","Indications may include but are not limited to, platinum resistant EOC, gastric\u002FGEJ cancer. HSNCC, NSCLC, TNBC, locally advanced or metastatic urothelial cancer and cervical cancer.",[13,50],"Drug: Paclitaxel",{"label":52,"type":10,"description":53,"interventionNames":54},"Phase 1b Dose Expansion of NX-1607 in combination with Paclitaxel","Indications may include but are not limited to, platinum resistant EOC, gastric\u002FGEJ cancer, HSNCC, NSCLC, TNBC, and locally advanced or metastatic urothelial cancer and cervical cancer",[13,50],{"label":56,"type":10,"description":57,"interventionNames":58},"Phase 1b Dose Expansion in MSS CRC","Patients with histologically confirmed MSS CRC, known KRAS WT, and must have been previously treated with \\> = 2 lines of systemic therapy including a fluoropyrimidine, irinotecan, and\u002For oxaliplatin (and EGFR inhibitor if known Ras wild type)",[13],[60,67],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":65},"DRUG","NX-1607","Oral NX-1607",[9,47,15,27,56,35,23,39,43,19,31,52],[66],"Cbl-b Inhibitor",{"type":61,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"Paclitaxel","Paclitaxel IV",[47,52],null,[73],{"name":74,"affiliation":5,"role":75},"Linda Neuman, MD","STUDY_DIRECTOR",[77],{"name":78,"role":79,"phone":80,"phoneExt":81,"email":82},"Nurix Therapeutics Patient Outreach","CONTACT","4152307815","7815","nx1607101@nurixtx.com",[84,98,115,128,146,160,174,189,203,217,231,243,252,266,279,293,302],{"facility":85,"status":86,"city":87,"state":88,"zip":89,"country":90,"countryCode":91,"cosmosGeoPoint":92,"geoPoint":97,"contacts":71},"City of Hope","COMPLETED","Duarte","California","91010","United States","US",{"type":93,"coordinates":94},"Point",[95,96],-117.97729,34.13945,{"lat":96,"lon":95},{"facility":99,"status":100,"city":101,"state":88,"zip":102,"country":90,"countryCode":91,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"University of Southern California","RECRUITING","Los Angeles","90007",{"type":93,"coordinates":104},[105,106],-118.24368,34.05223,{"lat":106,"lon":105},[109,112],{"name":110,"role":79,"phone":71,"phoneExt":71,"email":111},"Xiomara Menendez","Xiomara.Menendez@med.usc.edu",{"name":113,"role":79,"phone":71,"phoneExt":71,"email":114},"Lorraine Martinez","Lorraine.Martinez@med.usc.edu",{"facility":116,"status":100,"city":117,"state":88,"zip":118,"country":90,"countryCode":91,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"University of California, San Francisco","San Francisco","94158",{"type":93,"coordinates":120},[121,122],-122.41942,37.77493,{"lat":122,"lon":121},[125],{"name":126,"role":79,"phone":71,"phoneExt":71,"email":127},"Early Phase Clinical Trials","earlyphaseclinicaltrials@ucsf.edu",{"facility":129,"status":100,"city":130,"state":131,"zip":132,"country":90,"countryCode":91,"cosmosGeoPoint":133,"geoPoint":137,"contacts":138},"University of Colorado School of Medicine","Aurora","Colorado","80045",{"type":93,"coordinates":134},[135,136],-104.83192,39.72943,{"lat":136,"lon":135},[139,141,143],{"name":140,"role":79,"phone":71,"phoneExt":71,"email":71},"Brandi Asheim",{"name":71,"role":79,"phone":71,"phoneExt":71,"email":142},"BRANDI.ASHEIM@CUANSCHUTZ.EDU",{"name":144,"role":145,"phone":71,"phoneExt":71,"email":71},"Wells Messersmith, MD","PRINCIPAL_INVESTIGATOR",{"facility":147,"status":100,"city":148,"state":149,"zip":150,"country":90,"countryCode":91,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"University of Chicago","Chicago","Illinois","60637",{"type":93,"coordinates":152},[153,154],-87.65005,41.85003,{"lat":154,"lon":153},[157],{"name":158,"role":79,"phone":71,"phoneExt":71,"email":159},"Clinical Trials Office","cancerclinicaltrials@bsd.uchicago.edu",{"facility":161,"status":100,"city":162,"state":163,"zip":164,"country":90,"countryCode":91,"cosmosGeoPoint":165,"geoPoint":169,"contacts":170},"University of North Carolina","Chapel Hill","North Carolina","27599",{"type":93,"coordinates":166},[167,168],-79.05584,35.9132,{"lat":168,"lon":167},[171],{"name":158,"role":79,"phone":172,"phoneExt":71,"email":173},"919-966-4432","cancerclinicaltrials@med.unc.edu",{"facility":175,"status":100,"city":176,"state":177,"zip":178,"country":90,"countryCode":91,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"University of Oklahoma","Oklahoma City","Oklahoma","73104",{"type":93,"coordinates":180},[181,182],-97.51643,35.46756,{"lat":182,"lon":181},[185,187],{"name":186,"role":79,"phone":71,"phoneExt":71,"email":71},"Christina Caldwell",{"name":71,"role":79,"phone":71,"phoneExt":71,"email":188},"Christina-Caldwell@ouhsc.edu",{"facility":190,"status":100,"city":191,"state":192,"zip":193,"country":90,"countryCode":91,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"MD Anderson Cancer Center","Houston","Texas","77030",{"type":93,"coordinates":195},[196,197],-95.36327,29.76328,{"lat":197,"lon":196},[200],{"name":201,"role":79,"phone":71,"phoneExt":71,"email":202},"Rabia Khan","rkhan@mdanderson.org",{"facility":204,"status":100,"city":205,"state":206,"zip":207,"country":90,"countryCode":91,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"University of Virginia","Charlottesville","Virginia","22908",{"type":93,"coordinates":209},[210,211],-78.47668,38.02931,{"lat":211,"lon":210},[214],{"name":215,"role":79,"phone":71,"phoneExt":71,"email":216},"Chrystal Axford","CGP9E@uvahealth.org",{"facility":218,"status":100,"city":219,"state":220,"zip":221,"country":90,"countryCode":91,"cosmosGeoPoint":222,"geoPoint":226,"contacts":227},"Fred Hutchinson Cancer Center","Seattle","Washington","98109",{"type":93,"coordinates":223},[224,225],-122.33207,47.60621,{"lat":225,"lon":224},[228],{"name":229,"role":79,"phone":71,"phoneExt":71,"email":230},"Phase 1 Research Program","phase1clinicaltrial@fredhutch.org",{"facility":232,"status":100,"city":233,"state":234,"zip":235,"country":236,"countryCode":237,"cosmosGeoPoint":238,"geoPoint":242,"contacts":71},"Royal Marsden Hospital NHS Foundation Trust","Sutton","Surrey","SM2 5PT","United Kingdom","UK",{"type":93,"coordinates":239},[240,241],-0.2,51.35,{"lat":241,"lon":240},{"facility":244,"status":100,"city":245,"state":71,"zip":246,"country":236,"countryCode":237,"cosmosGeoPoint":247,"geoPoint":251,"contacts":71},"Addenbrookes Cambridge University Hospital","Cambridge","CB2 0QQ",{"type":93,"coordinates":248},[249,250],0.11667,52.2,{"lat":250,"lon":249},{"facility":253,"status":100,"city":254,"state":71,"zip":255,"country":236,"countryCode":237,"cosmosGeoPoint":256,"geoPoint":260,"contacts":261},"Beatson West of Scotland Cancer Centre","Glasgow","G12 0YN",{"type":93,"coordinates":257},[258,259],-4.25763,55.86515,{"lat":259,"lon":258},[262,264],{"name":263,"role":79,"phone":71,"phoneExt":71,"email":71},"Ruth Orr",{"name":71,"role":79,"phone":71,"phoneExt":71,"email":265},"Ruth.Orr@ggc.scot.nhs.uk",{"facility":267,"status":100,"city":268,"state":71,"zip":269,"country":236,"countryCode":237,"cosmosGeoPoint":270,"geoPoint":274,"contacts":275},"Sarah Cannon Research Institute","London","W1G 6AD",{"type":93,"coordinates":271},[272,273],-0.12574,51.50853,{"lat":273,"lon":272},[276],{"name":277,"role":79,"phone":71,"phoneExt":71,"email":278},"Referrals","Referrals.SCRI@hcahealthcare.co.uk",{"facility":280,"status":100,"city":281,"state":71,"zip":282,"country":236,"countryCode":237,"cosmosGeoPoint":283,"geoPoint":287,"contacts":288},"The Christie NHS Foundation Trust","Manchester","M20 4BX",{"type":93,"coordinates":284},[285,286],-2.23743,53.48095,{"lat":286,"lon":285},[289,291],{"name":290,"role":79,"phone":71,"phoneExt":71,"email":71},"The Christie Enquiries",{"name":71,"role":79,"phone":71,"phoneExt":71,"email":292},"the-christie.ECMT.enquiries@nhs.net",{"facility":294,"status":100,"city":295,"state":71,"zip":296,"country":236,"countryCode":237,"cosmosGeoPoint":297,"geoPoint":301,"contacts":71},"Northern Centre for Cancer Care","Newcastle","NE7 7DN",{"type":93,"coordinates":298},[299,300],-5.88979,54.21804,{"lat":300,"lon":299},{"facility":303,"status":86,"city":304,"state":71,"zip":305,"country":236,"countryCode":237,"cosmosGeoPoint":306,"geoPoint":310,"contacts":71},"Churchill Hospital","Oxford","OX3 7LE",{"type":93,"coordinates":307},[308,309],-1.25596,51.75222,{"lat":309,"lon":308},{"type":312,"investigatorFullName":71,"investigatorTitle":71,"investigatorAffiliation":71,"oldNameTitle":71,"oldOrganization":71},"SPONSOR","100447533","phase-1-a-study-of-nx-1607-in-adults-with-advanced-malignancies-100447533",false,"NCT05107674","A Study of NX-1607 in Adults With Advanced Malignancies","A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types","Key Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Measurable disease per disease-specific response criteria.\n* Patients must have disease that is metastatic or unresectable and have received standard treatment options, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Minimum of 3 weeks or 5 half-lives (whichever is shorter) since last dose of systemic cancer therapy (unless otherwise specified) or minimum of 2 weeks since last radiotherapy, or minimum of 6 weeks since last systemic therapy with nitrosoureas, antibody-drug conjugate, or radio immuno-conjugate therapy.\n* Adequate organ and bone marrow function, in the absence of growth factors (with limited exception for DLBCL), as defined by laboratory parameters.\n* Patients of child-bearing potential must use adequate contraceptive measures to avoid pregnancy for the duration of the study as defined in the protocol.\n* Patient must be willing and able to adhere to the prohibitions and restrictions specified in the protocol.\n* Each patient must sign an informed consent form (ICF).\n* Histological or cytological diagnosis of platinum-resistant EOC, including primary peritoneal and fallopian tube carcinoma; gastric\u002FGEJ cancer; HNSCC; recurrent and either metastatic or unresectable melanoma; NSCLC; mCRPC; MPM; TNBC; locally advanced or metastatic urothelial cancer; cervical cancer; MSS CRC; or DLBCL (including DLBCL-RT)\n* Accessible tumor (for all cohorts) or lymph node (DLBCL only) for biopsy (Phase 1b only).\n\nKey Exclusion Criteria:\n\n* Active untreated brain metastases.\n* Patient has any of the following:\n* Uncontrolled intercurrent illness including, but not limited to, poorly controlled hypertension or diabetes, or ongoing active infection requiring systemic therapy.\n* Patients with primary refractory EOC defined as patients who do not respond to their first platinum-containing regimen or who relapse less than 6 months after completion of that first platinum-containing regimen\n* Psychiatric illness that would limit compliance with study requirements.\n* Treatment with any of the following prior to the first dose of NX-1607: CPI (anti-PD-1, PD-L1, cytotoxic T-lymphocyte-associated protein 4, etc) within 3 weeks; autologous or allogeneic stem cell transplant within 100 days; prior systemic cancer therapy within 3 weeks or 5 half-lives (whichever is shorter) (unless otherwise specified) (including hormonal therapy except for hormonal prophylaxis for a prior malignancy); prior radiotherapy within 2 weeks; prior systemic therapy with nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy within 6 weeks; use of strong or moderate CYP3A4 inducers or inhibitors within 14 days or 7 days, respectively, or 5 half-lives (whichever is longer)\n* History of CAR-T therapy within 30 days prior to the first dose of NX-1607.\n* Toxicities from previous anti-cancer therapies that have not resolved to baseline levels or to Grade 1 or less except for Grade 2 alopecia and Grade 2 peripheral neuropathy or patients receiving endocrine replacement therapy\n* Patients who experienced Grade 3 or higher irAEs with prior immunotherapy.\n* History of uveitis, or an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.\n* Unable to swallow capsules or has malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of NX-1607.\n* Known allergies, hypersensitivity, or intolerance to components of NX-1607.\n* Pregnant, breastfeeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of NX-1607.\n* Patient is a man who plans to father a child while enrolled in this study or within 3 months after the last dose of NX-1607 and, as applicable, within 6 months after the last dose of paclitaxel.\n* Patient has had major surgery (e.g., requiring general anesthesia) within 4 weeks before the planned first dose of NX-1607, or will not have fully recovered from surgery, or has surgery planned during the time the patient is expected to participate in the study or within 4 weeks after the last dose of NX-1607. Note: Patients with minor planned surgical procedures to be conducted under local anesthesia may participate.\n* Vaccinated with a live vaccine within 28 days (with the exception of the annual inactivated influenza vaccine) or COVID-19 vaccination within 14 days prior to the first dose of NX-1607.\n* Active known second malignancy with the exception of any of the following:\n\n  * Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer.\n  * Adequately treated Stage I cancer from which the patient is currently in remission and has been in remission for ≥ 2 years.\n  * Low-risk prostate cancer with Gleason score \\\u003C 7 and PSA \\\u003C 10 ng\u002FmL.\n  * Any other cancer from which the patient has been disease-free for ≥ 2 years.\n* Infection with human immunodeficiency virus (HIV)-1 or HIV-2. Exception: Patients with well controlled HIV (e.g., CD4 \\> 350\u002Fmm3 and undetectable viral load) are eligible.\n* Current active hepatitis, including hepatitis A (hepatitis A virus immunoglobulin M \\[IgM\\] positive), hepatitis B (hepatitis B virus \\[HBV\\] surface antigen positive), or hepatitis C (hepatitis C virus \\[HCV\\] antibody positive, confirmed by HCV RNA). Patients with HCV with undetectable virus after treatment are eligible. Patients with prior exposure to HBV may be entered if quantitative PCR is negative.\n* Use of systemic corticosteroids (\\> 20 mg prednisone or equivalent) within 15 days (except for prophylaxis for radio diagnostic contrast reactions and\u002For prophylaxis for patients receiving paclitaxel), or other immunosuppressive drugs within 30 days, prior to the first dose of NX-1607.\n* Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 µg \\[NIH 2020\\] (Note: Patients who switch from a high dose to a dose of 30 µg\u002Fday or less at least 1 day prior to Screening assessments are eligible for study entry).\n* Receipt of an IP or has been treated with an investigational device within 3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NX-1607.\n* Any of the following within 6 months prior to the first dose of NX-1607 or ongoing:\n\n  * Myocardial infarction\n  * Unstable angina\n  * Unstable symptomatic ischemic heart disease\n  * New York Heart Association Class III or IV heart failure\n  * Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events)\n  * Any other significant cardiac condition (e.g., pericardial effusion, restrictive cardiomyopathy, severe untreated valvular stenosis, or severe congenital heart disease)\n  * Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating Investigator in consultation with the Medical Monitor.","ALL","18 Years",{"count":323,"type":324},345,"ESTIMATED","INTERVENTIONAL",[327],"PHASE1","This is a first-in-human Phase 1a\u002F1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.",[330,331,332,333,334,335,336,337,338,339,340,341,342,343],"Ovarian Cancer, Epithelial","Gastric Cancer","GastroEsophageal Junction (GEJ) Cancer","Head and Neck Squamous Cell Carcinoma","Metastatic or Unresectable Melanoma","Non-small Cell Lung Cancer (NSCLC)","Metastatic Castration-resistant Prostate Cancer (mCRPC)","Malignant Pleural Mesothelioma (MPM)","Triple Negative Breast Cancer (TNBC)","Metastatic Urothelial Carcinoma","Cervical Cancer","Diffuse Large B Cell Lymphoma (DLBCL)","Richter Transformation","Microsatellite Stable Colorectal Carcinoma",[345,346,347],"Ubiquitin Ligase Inhibitor","Advanced Malignancies","T-cell Activation","2025-09-05",{"date":350,"type":351},"2025-09-09","ACTUAL",{"date":353,"type":351},"2021-09-29",{"date":355,"type":324},"2028-02-28",{"name":5,"class":6},17]